INTRODUCTION
The risk of lymphoma is increased in several systemic autoimmune diseases, mainly Sj gren s syndrome, systemic lupus ö ' erythematosus and rheumatoid arthritis (RA) . In RA, the risk of non-Hodgkin s lymphoma (NHL) is increased by twofold and that of 1 ' 2 Hodgkin s lymphoma (HL) by threefold. Long-lasting inflammatory activity of RA is considered the main risk factor of lymphoma by its ' 3 continuous stimulation of B-cells.4 The effect of immunosuppressive drugs on the risk of lymphoma remains a matter of debate. To date, only the deleterious role of azathioprine has been demonstrated for both RA and Crohn s disease (CD) . Although withdrawal of methotrexate (MTX) treatment can ]4 ' 5 rarely induce regression of Epstein-Barr virus (EBV)-associated lymphoproliferation, most recent reports did not find any increased risk 6 of NHL in RA patients treated with MTX. , 7 8
Recent concerns about lymphoma have focused on therapy with anti-TNF drugs because of their profound immunoregulatory effect.
However, anti-TNF therapy could reduce the inflammatory activity of the underlying disease, which is the main risk factor for lymphoma in RA.
In some cohorts of RA patients receiving anti-TNF therapy, the risk of lymphoma was not different than that for RA patients not receiving the therapy. , However, these cohort studies were underpowered to investigate a difference between anti-TNF agents in 7 9 -11 terms of risk of lymphoma.
We aimed to examine whether patients receiving anti-TNF agents have an increased lymphoma risk and to compare risks for different anti-TNF agents, described the cases of lymphoma and their outcome, and identified the risk factors of lymphoma in patients receiving anti-TNF therapy.
PATIENTS AND METHODS
The French RATIO (Research Axed on Tolerance of bIOtherapies) registry was designed by a multidisciplinary group to prospectively collect all cases of lymphoma occurring in France from February 1, 2004 , to January 31, 2007 , in patients who were receiving anti-TNF therapy, for whatever the indication. The design has been described elsewhere. ,
The reporting of this study conforms to the 12 13 STROBE statement.14
Identification and validation of lymphoma cases
All cases reported to the 31 French pharmaco-vigilance regional centers of Agence Fran aise de S curit Sanitaire des Produits de ç é é Sant (AFSSAPS), or pointed out directly to the companies commercializing anti-TNF were collected. In addition, physicians from all the é different French hospital centers implied either in the prescription of TNF blockers (i.e. rheumatology, internal medicine, gastroenterology and dermatology departments) and/or in the management of lymphomas (i.e. hematology or oncology centers), were directly required to report each newly diagnosed case). A direct mail reminder 4 times a year and several communications at congresses or in specialized press encouraged them to report cases. of controls reflecting the proportion of patients receiving each of the three anti-TNF drug in France. Two controls per case were randomly matched by sex, age (within 5 years) and underlying inflammatory disease from this database of controls. We also used a second sample of controls randomly selected from the same database of controls, with the same matching criteria (second matching).
Validation of cases

Incidence study
Incidence of lymphoma
We estimated the annual incidence rate of lymphoma in patients treated with anti-TNF therapy, adjusted for age and sex, with the French population as a reference (see supplementary file for details).
Statistical analysis
The number of cases of lymphoma in France during the study period determined the sample size. A descriptive analysis was performed for the whole sample. We identified the risk factors of lymphoma by both univariate and multivariate analysis (conditional logistic regression model). The SIR was calculated for anti-TNF agents use as a whole and for agents used individually. We performed subgroup and sensitivity analyses. (see supplementary file for details).
Compliance with research ethics standards
This study was authorized by the ethic committee of AP-HP, GHU Nord (Institutional Review Board of Paris North Hospitals, Paris 7
University, AP-HP; authorization number 162 08). The registry was reported at clinicaltrials.gov (ClinicalTrials.gov Identifier: -NCT00224562).
RESULTS
Description of the cases
We collected data on 41 cases of lymphomas, and 38 cases were validated. Among them, 31 were NHL (26 B-cell and 5 T-cell), 5 HL and 2 Hodgkin s-like lymphoma. The characteristics of the cases are in .
' Table 1 Biopsy specimens were reviewed for 36 cases (29 NHL, 5 HL and 2 Hodgkin s-like lymphomas). EBV was detected in 2 of 2 Hodgkin 
Time occurrence of lymphoma with anti-TNF therapy
The median time from onset of anti-TNF treatment and the first symptoms of lymphoma was 23.6 months. In 5 patients, lymphoma occurred, but anti-TNF therapy had been discontinued 6.1 to 44.1 months before. For these 5 patients, the last anti-TNF agent received was infliximab for 3 and adalimumab for 2. As indicated in , the relation between cumulative frequency of lymphoma and time Figure 1 from onset of anti-TNF therapy appeared to be approximately linear for the first or last anti-TNF agent received and did not differ by drug received.
Risk factors of lymphoma for patients receiving anti-TNF therapy
The case-control study involved 37 cases and 74 controls (as described in the methods, the patient treated for Sj gren s syndrome was Table 2 On the multivariate analysis ( ), 2 factors were independently associated with occurrence of lymphoma in patients receiving Table 3 anti-TNF therapy: anti-TNF treatment duration less than 2 years (OR 3.30 1.17 9.30 ) and treatment with infliximab or adalimumab
Page / 4 14 versus etanercept (OR 4.12 1.36 12.49 and OR 4.73 1.27 17.65 , respectively). In the case-control study restricted to RA cases, only
one factor was associated with occurrence of lymphoma: treatment with infliximab or adalimumab versus etanercept (OR 6.68 1.90 = [ -23.54 ). The ORs of adalimumab or infliximab versus etanercept were also very similar with the second matching and in subgroup and ] sensitivity analyses ( ). Figure 2 
Incidence and risk of lymphoma for patients receiving anti-TNF therapy compared with the general population
The main analysis relied on a total number of 57,711 patient-years of use of anti-TNF therapy during the 2004 2006 period, as the denominator of the incidence rate. The annual incidence rate of lymphoma adjusted for age and sex among patients receiving anti-TNF therapy, with the French population as a reference, was 42.1 (95 CI 6.9 77.2 per 100,000 person-years). The SIR was 2.4 (95 CI 1.7 % -% -3.2; p<0.0001) ( ). For RA and SpA, the SIR was 2.3 (1.6 3.3; p<0.0001) and 1.9 (0.9 4.0; p 0.09), respectively. Figure 3 --= Like for the case-control study, the incidence of lymphoma for patients receiving anti-TNF therapy differed depending on the agent etanercept and monoclonal-antibody therapy in the main analysis and in the sensitivity analyses ( ), even when we separately used Figure 3 the different estimates from independent sources, which gave very consistent adjusted incidence rates and SIRs (supplementary Figure 1 ).
DISCUSSION
This 3-year study is the first national prospective study recording all cases of lymphoma in patients receiving anti-TNF agents, whatever the underlying disease. This study allowed us to collect enough cases to differentiate between lymphoma risk by use of anti-TNF agent. We found higher incidence of lymphoma with use of the two monoclonal-antibody agents (adalimumab and infliximab) than with the solublereceptor agent (etanercept).
Three cohorts of RA patients have been used to compare treatment with anti-TNF agents and with classical disease-modifying anti-rheumatic drugs in terms of risk of lymphoma; , and did not found an increased risk with anti-TNF agents (relative risk of 1.0 7 9 -11 [ 0.6 1.8 , 1.35 0.82 2.11 and 1.11 0.51 2.37 ) These studies failed to demonstrate a difference between the treatments in risk of
lymphoma due to insufficient power. Although the design of the RATIO study has some limitations, it is probably the only way (or at least the most powerful way) to investigate difference in risk with use of anti-TNF agents.
Our study may have some limitations
The denominator of the incidence rate was estimated only. However, because each firm evaluated the number of patient-years in the period for each anti-TNF agent, the difference in risk between agents we observed cannot be explained by different methodologies used for the different agents. Furthermore, in the sensitivity analyses, the different estimates from independent sources gave very consistent adjusted incidence rates and SIRs (supplementary Figure 1 ).
Despite the different strategies used to identify all the cases in the whole country, we cannot exclude that some cases were missed. We make the assumption that reporting was equal with each biologic.. Actually, reporting of adverse events could be lower in patients treated sub-cutaneously (SC; i.e. etanercept and adalimumab) outside the hospital. But, in France, the SC-treated patients are mandatory seen by hospital physicians initially and yearly for renewal. Moreover, the lack of AE reporting is a main issue for minor side effects but not for life-threatening side effects, particularly lymphomas that are a major concern for physicians and patients regarding anti-TNF agents.
Furthermore, the patients treated with anti TNF agents that have lymphomas could be notified to RATIO by the anti TNF agent prescribor (rheumatologist, gastro-enterologist, internist or others), by the onco-haematologist, or by the pharmacovigilance regional center. Finally, we found that the risk of lymphoma was similar for adalimumab and infliximab, that share the same mechanism of action (different from the one of etanercep), but adalimumab is a S.C. anti TNF agent and infliximab I. V. anti TNF agent.
Finally, the cumulative activity of the disease, known as a risk factor of lymphoma at least for RA patients, could be different among 4 patients receiving the different anti-TNF agents. Indeed, disease in patients receiving therapy at the beginning of anti-TNF availability (before 2002), was probably more severe, and such patients received exclusively infliximab (the only anti-TNF available in France at that time). However, patients with anti-TNF onset before 2002 did not have a higher risk of lymphoma than others (anti-TNF onset before 2002: OR 1.3 0.5 3.7 ; p 0.60). Furthermore, the comparison between the type of drug used and risk was adjusted on the time from onset
of anti-TNF treatment ( ). In addition, indirect markers of disease activity (median duration of the inflammatory underlying disease, Table 3 percentage of patients treated with steroids, frequency of positive rheumatoid factor and anti-CCP in RA patients) were not greater in patients treated with infliximab or adalimumab than in those treated with etanercept (data not shown). Lastly, the impact of a putative difference in duration of exposure and in disease activity depending on year of introduction of the anti-TNF agent probably cannot explain the difference in incidence of lymphoma depending on the type of anti-TNF agent used because we observed exactly the same increased Lymphoma complicating anti-TNF therapy Ann Rheum Dis . Author manuscript Page / 5 14 risk of lymphoma for patients receiving infliximab, which was introduced in 1999, and adalimumab, which has been available since 2004, whereas the risk was lower with use of etanercept, available in France from early 2003.
The strengths of this study are that our population of focus was the whole French population receiving anti-TNF therapy, whatever the indication for use, rather than a limited and selected population included in a specific cohort study. Furthermore, all the cases were validated by an expert committee, and the biopsy specimens were centralized, reviewed by the same hematopathologist and tested for EBV.
Even though the overall risk of lymphoma in RA patients treated with anti-TNF therapy does not appear to differ greatly from what is expected in a population of patients with inflammatory diseases, the risk differs depending on the anti-TNF drug used (higher risk with 1 -3 monoclonal anti-TNF therapy, adalimumab and infliximab). This difference in risk depending on agent was found in the case-control study and confirmed in the comparison of incidence with the general population, which supports the robustness of this finding. A meta-analysis assessing cancers in randomized controlled trials using monoclonal anti-TNF therapy, adalimumab and infliximab in RA patients revealed The absence of intrinsic increased risk of lymphoma in SpA patients makes this population an ideal model for assessing the anti-TNF-related risk of lymphoma. In our study, no significant increase in risk of lymphoma was observed in patients receiving 19 anti-TNF therapy for SpA. However, no definitive conclusion may be drawn from our data based on very few cases of lymphoma in SpA patients. Some of the cases we observed reinforce the likelihood of a causal role of anti-TNF therapy in risk of lymphoma. In one patient with AS who never received other immunosuppressors, including MTX, EBV-associated Hodgkin s-like lymphoma developed after ' treatment with infliximab. We observed 3 cases of EBV-induced lymphoproliferation: 2 cases of EBV-associated Hodgkin s-like ' lymphomas with infliximab treatment (one with RA, one with AS described above) and 1 case of EBV-associated B-cell NHL in a patient with RA treated with adalimumab. These 3 cases demonstrate that lymphomas similar to post-transplant lymphoproliferative disease may occur, even rarely, with anti-TNF treatment. In the literature, one case of EBV-associated lymphoproliferation in a patient with RA treated with etanercept regressed after withdrawal of the drug.
Another case of hypopharynx MALT lymphoma not associated with EBV 20 regressed spontaneously after withdrawal of infliximab. 21
The pathophysiological mechanism inducing a higher risk of lymphoma in patients receiving anti-TNF therapy remains unclear. A direct action of TNF or anti-TNF on B cells was hypothesized, but no increase in survival or apoptosis with TNF or infliximab treatment was found. 23 Actually, in inflammatory diseases and especially RA, the 3 anti-TNF agents may have opposite effects: a beneficial effect due to the decrease in activity of the disease and a deleterious effect due to immunomodulatory activity, which may concern EBV-associated lymphoma but also more classical lymphoma. The mechanism of action of this deleterious effect is still unknown but could be related to T-cell control of viruses such as EBV or of other mechanisms of lymphomagenesis. This T-cell control may require integrity of membrane TNF, which is upregulated in activated T cells. Some studies suggest a higher efficacy of anti-TNF monoclonalantibody treatment than TNF soluble receptor therapy for inhibiting membrane TNF signaling, which could lead to a decreased immune surveillance of different 22 mechanisms of lymphomagenesis.
In conclusion, some lymphomas associated with immunosuppression may occur in such patients. The incidence of lymphoma is higher with monoclonal-antibody agents than with the soluble receptor. This may be due to a difference of targeting membrane TNF, leading also to difference of effectiveness in some diseases such as Crohn s disease or granulomatous diseases.
'
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Figure 1
Time from onset of first and last anti-TNF treatment and first symptoms of lymphoma (months)
Figure 2
Estimation of the standardized incidence ratio (SIR) for risk of lymphoma according to underlying disease, and the histological subtype of lymphoma n is the number of cases involved in the calculation (numerator of the incidence rate) the plot size relates to the number of patients treated involved in the calculation (denominator of the incidence rate)
Figure 3
Sensitivity analysis of the results of the case-control analysis: odds ratios (ORs) for the risk of being treated with adalimumab or infliximab rather than with etanercept in multivariate analysis. n is the number of cases involved in the calculation the plot size relates to the number of patients treated involved in the calculation First anti-TNF agent received Etanercept 11 (29.7 )
